Assessing the impact of glaucoma and its treatment on the person

评估青光眼及其治疗对人的影响

• 批准号: 8953499
• 负责人: DAVID C MUSCH
• 金额: $ 19.38万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-01 至 2017-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8953499
• 关键词: Address; Adverse effects; Affect; Applications Grants; Biological Preservation; Blindness; Characteristics; Clinic; Clinical Research; Clinical Trials; Clinical assessments; Cohort Studies; Data; Data Analyses; Databases; Diagnosis; Diagnostic; Disease; Education; Epidemiologic Studies; Eye; Eye diseases; Eyedrops; Frequencies; Glaucoma; Goals; Health; Individual; Lead; Measurement; Measures; Medical; Mental Depression; Methodology; Methods; Monitor; National Eye Institute; Nature; Newly Diagnosed; Open-Angle Glaucoma; Outcome; Outcome Measure; Participant; Patient Care; Patient Outcomes Assessments; Patient Self-Report; Patients; Persons; Pharmaceutical Preparations; Prevalence; Provider; Reporting; Research; Research Personnel; Severities; Symptoms; Testing; Time; Treatment Protocols; Treatment outcome; United States; Vision; Vision Disorders; Visual; Visual Acuity; Visual Fields; Visual impairment; base; blind; depressive symptoms; experience; follow-up; improved; insight; monocular; optic nerve disorder; pressure; prevent; programs; public health relevance

 DESCRIPTION (provided by applicant): Glaucoma is one of the leading causes of visual impairment and blindness worldwide and in the United States. While glaucoma is usually a condition that affects both eyes, clinical assessments of its impact on patients in typical eye car settings are performed on each eye separately. This belies the fact that people affected by glaucoma function with both eyes, and treatments used to control glaucoma may impact on the person rather than only on the eye, even when those treatments are administered to only one eye. The overarching aim of the proposed research in this grant application is to assess the impact of glaucoma on the person rather than on the eye. Glaucoma has been associated with depression, and so we intend to evaluate depression in newly diagnosed glaucoma patients from the time of diagnosis through 9 years of follow-up during treatment, with respect to its prevalence and predictors. The typical approach to treating glaucoma involves frequent administration (often two or three times per day) of one or more topical medications (eye drops) to control eye pressure. Each type of medication has a unique set of potential symptoms associated with its use. We wish to relate reported ocular and systemic symptoms over time for a specific medication and after the addition of a second medication. The purpose of treatment is to control glaucoma, and the way that is typically measured is by means of a visual field test of each eye. Since a person with glaucoma uses both eyes to function, we wish to explore the relationship of visual function measures like the visual field test, when it is assessed using both eyes, with methods used to combine visual function measures taken on each eye separately, which is the typical test done in the clinic, to represent binocular visual function. All of these aims depend on data collected from over 600 participants in a clinical trial of initial treatments for glaucoma, the Collaborative Initial Glaucoma Treatment Study. The proposed research relates closely with the goals of the National Eye Institute, to support applied clinical research concerning the blinding eye diseases, visual disorders, mechanisms of visual function, preservation of sight, and the special health problems and needs of individuals who are partially-sighted or blind.

 描述（由申请人提供）：青光眼是全世界和美国视力障碍和失明的主要原因之一。虽然青光眼通常是一种影响双眼的疾病，但在典型的眼科汽车环境中，需要对每只眼睛分别进行其对患者影响的临床评估。这掩盖了这样一个事实：青光眼患者的双眼都有功能，用于控制青光眼的治疗可能会对患者产生影响，而不仅仅是对眼睛产生影响，即使这些治疗只针对一只眼睛进行。本拨款申请中拟议研究的总体目标是评估青光眼对人而不是对眼睛的影响。青光眼与抑郁症相关，因此我们打算评估新诊断青光眼患者从诊断时到治疗期间随访 9 年的抑郁症患病率和预测因素。治疗青光眼的典型方法包括频繁施用（通常每天两到三次）一种或多种外用药物（滴眼剂）来控制眼压。每种类型的药物都有一组与其使用相关的独特潜在症状。我们希望将特定药物随时间变化以及添加第二种药物后报告的眼部和全身症状联系起来。治疗的目的是控制青光眼，通常的测量方法是通过每只眼睛的视野测试。由于青光眼患者使用双眼发挥功能，因此我们希望探讨视功能测量（例如视野测试）在使用双眼进行评估时的关系 眼睛，采用结合分别对每只眼睛进行的视觉功能测量的方法，这是临床上进行的典型测试，以代表双眼视觉功能。所有这些目标都取决于青光眼初始治疗临床试验（青光眼初始治疗合作研究）中收集的 600 多名参与者的数据。拟议的研究与国家眼科研究所的目标密切相关，支持有关致盲眼病、视觉障碍、视觉功能机制、视力保护以及弱视或失明者的特殊健康问题和需求的应用临床研究。